EUVIMEDEUVIMED entdecken
Crossref

Descriptive Analysis of Valsartan-Related Adverse Events Reported in the FAERS Database

Nehad Jaser Ahmed

Clinical Pharmacy Connect · 25.03.2026 · 2 (1) · 1

DOI: 10.69709/cpc.2026.180140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacy Connect, online erschienen am 25.03.2026. Verfasst von Nehad Jaser Ahmed. Die Arbeit nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The angiotensin II receptor blocker valsartan, approved by the Food and Drug Administration (FDA), is indicated for the treatment of hypertension in adults and children aged one year and older, reduces hospitalizations due to heart failure, and improves survival following myocardial infarction (MI). Valsartan is widely used across adult populations; safety and effectiveness depend on patient factors and appropriate monitoring. Compared with ACE inhibitors, valsartan is associated with a lower incidence of cough. Reported adverse effects may include headache, nausea, and dizziness. FAERS reports through March 31, 2025, listing valsartan as the primary suspect drug, were retrieved using the term ‘valsartan’ and included in the analysis. Only reports containing complete information, including drug name, adverse event, and patient data, were considered. Adverse events were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms. The FDA Adverse Event Reporting System (FAERS) recorded 36,323 adverse events (AEs) associated with valsartan. High blood pressure was the most common adverse event associated with valsartan (13.38%). The next in order were dizziness (6.39%), therapeutic ineffectiveness (5.81%), and dyspnea (5.17%). Analysis of FAERS data indicates the potential for adverse effects associated with valsartan, including headache, dizziness, hypertension, lack of efficacy, and dyspnea. These findings emphasize the importance of appropriate dosing and monitoring, particularly in high-risk patients.

Zitieren

APA

Ahmed, N. J. (2026). Descriptive Analysis of Valsartan-Related Adverse Events Reported in the FAERS Database. Clinical Pharmacy Connect, 2(1), 1. https://doi.org/10.69709/cpc.2026.180140

Vancouver

Ahmed NJ. Descriptive Analysis of Valsartan-Related Adverse Events Reported in the FAERS Database. Clinical Pharmacy Connect. 2026;2(1):1. doi:10.69709/cpc.2026.180140

BibTeX
@article{Ahmed2026,
  author = {Ahmed, Nehad Jaser},
  title = {Descriptive Analysis of Valsartan-Related Adverse Events Reported in the FAERS Database},
  journal = {Clinical Pharmacy Connect},
  year = {2026},
  volume = {2},
  number = {1},
  pages = {1},
  doi = {10.69709/cpc.2026.180140}
}
Kostenlos starten →